Trials / Completed
CompletedNCT05560360
A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects
Study of the Pharmacokinetic Effects of Efavirenz on the Pharmacokinetics of SHR1459 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study used a single-dose, open and fixed sequence design to compare the pharmacokinetics in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR1459 tablet | 100 mg/tablet; administered orally |
| DRUG | Efavirenz tablet | 600 mg/tablet; administered orally |
Timeline
- Start date
- 2022-11-04
- Primary completion
- 2022-12-02
- Completion
- 2023-01-27
- First posted
- 2022-09-29
- Last updated
- 2023-02-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05560360. Inclusion in this directory is not an endorsement.